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Abstract
Background: Antigen B (EgAgB) is an abundant lipoprotein released by the larva of the cestode Echinococcus
granulosus into the host tissues. Its protein moiety belongs to the cestode-specific family known as hydrophobic
ligand binding protein (HLBP), and is encoded by five gene subfamilies (EgAgB8/1-EgAgB8/5). The functions of
EgAgB in parasite biology remain unclear. It may play a role in the parasite’s lipid metabolism since it carries host
lipids that E. granulosus is unable to synthesise. On the other hand, there is evidence supporting immuno-
modulating activities in EgAgB, particularly on innate immune cells. Both hypothetical functions might involve
EgAgB interactions with monocytes and macrophages, which have not been formally analysed yet.
Methods: EgAgB binding to monocytes and macrophages was studied by flow cytometry using inflammation-
recruited peritoneal cells and the THP-1 cell line. Involvement of the protein and phospholipid moieties in EgAgB
binding to cells was analysed employing lipid-free recombinant EgAgB subunits and phospholipase D treated-
EgAgB (lacking the polar head of phospholipids). Competition binding assays with plasma lipoproteins and ligands
for lipoprotein receptors were performed to gain information about the putative EgAgB receptor(s) in these cells.
Arginase-I induction and PMA/LPS-triggered IL-1β, TNF-α and IL-10 secretion were examined to investigate the
outcome of EgAgB binding on macrophage response.
Results: Monocytes and macrophages bound native EgAgB specifically; this binding was also found with lipid-free
rEgAgB8/1 and rEgAgB8/3, but not rEgAgB8/2 subunits. EgAgB phospholipase D-treatment, but not the
competition with phospholipid vesicles, caused a strong inhibition of EgAgB binding activity, suggesting an indirect
contribution of phospholipids to EgAgB-cell interaction. Furthermore, competition binding assays indicated that this
interaction may involve receptors with affinity for plasma lipoproteins. At functional level, the exposure of
macrophages to EgAgB induced a very modest arginase-I response and inhibited PMA/LPS-mediated IL-1β and
TNF-α secretion in an IL-10-independent manner.
Conclusion: EgAgB and, particularly its predominant EgAgB8/1 apolipoprotein, are potential ligands for monocyte
and macrophage receptors. These receptors may also be involved in plasma lipoprotein recognition and induce an
anti-inflammatory phenotype in macrophages upon recognition of EgAgB.
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Background
Cystic echinococcosis is a worldwide zoonotic infection
caused by the larval stage of Echinococcus granulosus
sensu lato species complex, which includes at least seven
species that affects humans and livestock with significant
economic and public health impact [1–5]. The larvae
(metacestodes) of these species are fluid-filled, bladder-
like structures that establish and gradually grow in the
parenchyma of host internal organs, most commonly
liver and lungs. They are usually called hydatid cysts, al-
though strictly the term cyst includes a fibrous adventitial
layer generated as a consequence of the host inflammatory
reaction. Once the larva matures and reaches fertility, it
generates protoscolex (PE), which are the parasite forms
capable of developing into the adult worm in the definitive
host (usually dogs). The fluid contained within the cyst,
known as hydatid cyst fluid (HF), collects a variety of
products excreted or secreted by the cellular, germinal
layer (GL) of the cyst wall, as well as by protoscoleces. In
addition, HF collects a variety of host plasma proteins
(mostly albumin and immunoglobulins) which cross the
cyst wall by unidentified mechanisms. This work refers to
E. granulosus sensu lato, but for simplicity we will use the
term E. granulosus.
One of the major HF components synthesised in abun-
dance by the larva is a lipoprotein named Antigen B
(EgAgB) [6]. The composition and antigenicity of EgAgB
has been extensively studied, due to the fact that it con-
stitutes the most immunogenic and specific Echinococ-
cus-genus antigen for human serodiagnosis [7–10].
Molecular studies for characterising EgAgB protein moi-
ety showed that it is encoded by a polymorphic and mul-
tigenic family that comprises five subfamilies named
EgAgB1 to EgAgB5 [11–17]. These genes are differen-
tially expressed in single lifecycle stages of the parasite,
as well as within distinct tissues of a given developmen-
tal stage. EgAgB1 to EgAgB4 are expressed in the meta-
cestode stage whereas EgAgB5 seems to be mostly
expressed in the adult stage. Regarding the metacestode,
the expression of all genes was detected in GL, being
EgAgB1 and EgAgB3 the most abundant, while in PE
EgAgB3 seems to be over-represented [18].
The mature protein products of EgAgB genes are α-
helix rich polypeptides of 8 kDa, referred to as EgAgB8/
1 to EgAgB8/5 subunits or apolipoproteins. Interestingly,
EgAgB was found to belong to a novel cestode-specific
family known as Hydrophobic Ligand Binding Proteins
(HLBPs) [19], which have emerged by independent gene
expansion events in different species [18]. More recently,
our group has made substantial progress in the bio-
chemical characterisation of EgAgB by developing novel
methodological tools for purifying and characterising the
lipid-free EgAgB8 apolipoproteins [20], and by determin-
ing which are its native lipid components [21]. We
showed that in vitro lipid-free EgAgB8 subunits oligo-
merise; which agrees with their electrostatic profile pre-
dicted by structure modelling [22, 23]. They bound
lipids selectively, particularly phospholipids and fatty
acids rather than cholesterol [20], confirming previous
observations [19]. Binding of lipids may enhance the
oligomerisation of EgAgB8 subunits, favouring the for-
mation of large lipoprotein complexes. We showed that
the native antigen is a large (about 230 kDa in mass)
lipoprotein particle, in which lipids account for about
one-half of EgAgB total mass, comprising a heteroge-
neous mixture of neutral (mainly triacylglycerides,
sterols and sterol esters) and polar lipids (mainly phos-
phatidylcholine) [21]. In sum, EgAgB may adopt a struc-
tural organisation similar to that of vertebrate high
density lipoprotein (HDL), in which around a dozen
EgAgB8 apolipoproteins would be embedded in an outer,
hydrophilic phospholipid layer that surrounds the hydro-
phobic core of the lipoprotein particle [23].
We have thus achieved a better knowledge of EgAgB
chemical composition and physicochemical properties.
However, the understanding of the role of EgAgB in the
parasite adaptation to host environment is still very rudi-
mentary. It is uncertain how and when EgAgB is trans-
ported outside of the hydatid cyst; its apparent absence
in the laminar layer as well as in the apical side of the
tegumental syncytium of the GL does not support the
existence of active secretion mechanisms in GL for this
transport [24, 25]. Nevertheless, the fact that the host
mounts a strong specific antibody response against EgAgB
reveals that it reaches host tissues. Furthermore, an EgAgB
ortholog in Taenia solium (TsM 150 kDa HLBP) was
localised within the granuloma, adjacent to host paren-
chyma cells [26]. EgAgB contains lipids that E. granulosus
is not able to synthesise [27, 28], such as fatty acids and
cholesterol, and this supports the idea that EgAgB partici-
pates in parasite’s lipid metabolism (reviewed by [23]). Al-
ternatively, EgAgB effects on various innate immune cells,
including neutrophils, monocytes and dendritic cells [29–
32], have led to the concept that this antigen is capable of
modulating local inflammation and the subsequent mech-
anisms that activate T lymphocytes, favouring the gener-
ation of a Th2-type specific response [31]. Nevertheless,
this Th2-biasing activity needs to be verified using the na-
tive lipoprotein, since it was described using denatured
EgAgB (purified using electroelution [28] or after heating
at 100 °C [31]). In any case, a putative EgAgB role in para-
site mechanisms associated with lipid metabolism or
immunomodulation would involve a direct interaction be-
tween EgAgB and host cells, likely mediated by cell recep-
tors, and these interactions have not been examined yet.
In this work, we studied the ability of monocytes and
macrophages to bind EgAgB selectively as well as the
impact of EgAgB binding on the activation phenotype of
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macrophages. Our results show that EgAgB, particularly
its apolipoprotein component, binds to monocytes and
macrophages specifically, using receptors shared with
plasma lipoproteins. Furthermore, EgAgB receptors in
macrophages seem to induce signalling events involved




(BHT), cell culture reagents, dimethyl sulfoxide (DMSO),
inorganic salts, ovalbumin (OVA), L-arginine, lipopolysac-
charides (LPS) from Escherichia coli, phorbol 12-myristate
13-acetate (PMA), reduced glutathione, RPMI 1640 cul-
ture medium, streptavidin-peroxidase, 3,3′,5,5′-tetra-
methylbenzidine (TMB), thrombin from human plasma
and urea were acquired from Sigma Chemicals (USA).
Ethylenediaminetetraacetic acid (EDTA) and potassium
bromide were obtained from Applichem (Germany).
Acetonitrile was purchased from JT Baker (USA) and tri-
fluoroacetic acid from Merck (Germany). Gluthathione
Sepharose 4B and Q-Sepharose resins were acquired from
GE Healthcare Life Sciences (Sweden). C8-bonded silica
column was purchased from Vydac (USA). Human
monocyte-like THP-1 cell line was obtained from Ameri-
can Type Culture Collection (ATCC, USA). Fetal bovine
serum (FS) was purchased from Gibco (USA) and N-
Hydroxysuccinimide-Biotin (NHS-Biotin) was acquired
from Pierce (USA). Phospholipase D (PLD) was obtained
from Calbiochem (Germany). Monoclonal antibody (mab)
against EgAgB8/1 subunit (EB7 mab) was generously
donated by Dr. Gualberto González (Cátedra de Inmuno-
logía, Facultad de Química, UdelaR). Flow cytometry anti-
bodies were purchased from BD Biosciencies or Biolegend
(USA). Phosphatidylcholine (PC) and phosphatidylserine
(PS) were obtained from Avanti Polar Lipids (USA).
Mice
Wild type C57BL/6J and BALB/c mice as well as LDL-
receptor (LDLr) deficient mice on the C57BL/6J back-
ground (B6.129S7-Ldlrtm1Her) were acquired from
Pasteur Institute of Montevideo (Uruguay). Animal ma-
nipulation and husbandry were done in accordance with
the ethical committee guidelines of the Honorary Commis-
sion of Animal Experimentation (CHEA) from UdelaR.
Parasite material
E. granulosus bovine hydatid cysts were obtained from
liver and lungs of naturally infected animals, collected
during the routine work of local abattoirs in
Montevideo (Uruguay). Infertile HF were obtained by
aseptic aspiration of the cyst content, preserved by
addition of 5 mM EDTA and 20 μM BHT, and main-
tained at −20 °C until use.
Purification of native EgAgB
Purification of native EgAgB was achieved employing a
two-step procedure. A pool of individual HF (at least a
volume of 2 L, collected from an average of 15 hydatid
cysts) was prepared and clarified by centrifugation at
10000 g followed by filtration through 0.45 μm filter
membrane (Millipore). The clarified HF was then
fractionated by anion exchange chromatography on a Q-
Sepharose column, using 20 mM phosphate, pH 7.5 con-
taining 200 mM NaCl, 5 mM EDTA and 20 μM BHT as
equilibration buffer, and changing the ionic strength to
500 mM NaCl in a single step for elution. The eluted
fraction (fQS) was concentrated 10-fold using a Savant
SpeedVac System and equilibrated in phosphate buffered
saline (PBS) containing 5 mM EDTA and 20 μM BHT
(PBSEB) with a PD-10 desalting column (Amersham,
Biosciences). EgAgB was then purified by ultracentrifu-
gation of fQS in a KBr density gradient. 2.45 g of KBr
were dissolved in 5 ml of fQS in an ultracentrifuge tube
and slowly covered with a solution containing 0.15 M
NaCl and 0.42 M KBr. After ultracentrifugation (4 h at
332000 g) two yellowish bands were obtained. EgAgB
was recovered in the yellow-brown, low density fraction.
The homogeneity of EgAgB preparation was analysed by
SDS-PAGE on 15 % polyacrylamide gels followed by
Coomassie staining. At least two consecutive ultracentri-
fugation rounds were performed to achieve a good-
quality EgAgB preparation (higher than 95 % purity).
Finally, EgAgB was equilibrated in PBSEB and main-
tained at 4 °C under N2 atmosphere until use. Five dif-
ferent EgAgB preparations were used during this work.
The apolipoprotein composition of native EgAgB was
determined by LC-MS/MS, using an LTQ-Orbitrap
Velos mass spectrometer (Thermo Scientific). Proteins
were identified using MaxQuant software (v.1.5.3.8) by
searching MS and MS/MS data against the Echinococcus
database; this database was built in house comprising all
Echinococcus granulosus G1 sequences (published in
www.genedb.org as EGU_proteins_29042013_products.fa)
plus a total of 107 sequences, including polymorphic vari-
ations at the level of the mature products as well as the
orthologous products in E. granulosus s.l. and E. mul-
tilocularis (available on NCBInr). Statistical analysis
for protein identification was performed using Perseus
(v. 1.4.0.11) on the basis of unique peptide MS inten-
sities and the presence of a minimum of two unique
peptides. For evaluating the abundance of EgAgB8
subunits in samples, intensity-based absolute quantifi-
cation (iBAQ) was used since it has been reported as
a useful label-free quantification method provided by
MaxQuant [33]. The relative abundance of a particu-
lar EgAgB8 subunit was then estimated as the per-
centage of the total iBAQ intensity corresponding to
EgAgB apolipoproteins.
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For functional assays on macrophages native EgAgB
was purified by immunoaffinity chromatography employ-
ing the EB7 mab as described by González et al. [13]
(immunopurified EgAgB) to exclude pyrogens which may
affect cell functions even at trace levels.
Purification of recombinant lipid-free EgAgB8 subunits
Purification of recombinant lipid-free EgAgB8 subunits
(rEgAgB8) was undertaken employing a protocol pre-
viously described [20]. Briefly, rEgAgB8/1, rEgAgB8/2
and rEgAgB8/3 subunits (corresponding to [Uniprot:
Q9UA06, Q27275 and Q95NW6, respectively]) were
purified as Glutathione-S-Transferase fusion proteins
by affinity chromatography on immobilised glutathi-
one and recovered by thrombin cleavage. Delipidation
of rEgAgB8 subunits was achieved by reversed-phase
high-performance liquid chromatography (RP-HPLC)
in an HPLC System (Merck-Hitachi, Japan) with C8-
bonded silica as stationary phase and water/acetonitrile/
trifluoroacetic acid mobile phase. The purity of lipid-free
rEgAgB8 subunits was monitored by SDS-PAGE on
15 % polyacrylamide gels followed by Coomassie
staining. Lipid-free rEgAgB8 subunits were maintained
at −80 °C until use.
Biotin labelling of EgAgB
Biotinylation of native EgAgB was carried out by adding
80 μL of a fresh solution of NHS-Biotin (5 mg/mL in
DMSO) per mg of protein in sodium carbonate 0.1 M,
pH 9.0. In the case of lipid-free rEgAgB81, rEgAgB8/2
and rEgAgB8/3 subunits, we used an NHS-Biotin con-
centration sufficient to label a maximum of six lysines
per molecule in each subunit. The mixture was incu-
bated during 4 h at room temperature under continuous
stirring. Excess NHS-Biotin was removed by extensive
dialysis against PBSEB. Biotinylated rabbit IgG, as well as
OVA labelled under the conditions described above were
employed as controls. Protein biotinylation was moni-
tored by adsorbing the biotinylated proteins on an
ELISA microplate and using streptavidin-peroxidase
and TMB for developing. Under these labelling condi-
tions, the extent of biotinylation was similar between
EgAgB (native or recombinant subunits) and the pro-
tein control (OVA), as wells as among rEgAgB8 sub-
units (Additional file 1).
EgAgB treatment with phospholipase D
Native EgAgB was treated with PLD (10 U PLD/mg
EgAgB) for 24 h at 37 °C in 30 mM Tris–HCl, 2 mM
CaCl2, 100 mM NaCl, pH 8.0. After treatment, PLD was
removed by ultracentrifugation of EgAgB particles in a
KBr gradient as described above (EgAgBPLD+). In
parallel EgAgB was treated without adding PLD
(EgAgBPLD-) as a control of treatment. Effective PLD
treatment was analysed by lipid extraction and high
performance thin layer chromatography (HPTLC) as
previously described [21].
Purification of plasma lipoproteins
LDL and HDL were isolated from normal human plasma
obtained from healthy volunteers after informed con-
sent. Isolation was performed following a described pro-
cedure based on ultracentrifugation in a KBr density
gradient [34]. After ultracentrifugation, LDL and HDL
were extensively dialysed against PBSEB, maintained at
4 °C and under N2 atmosphere, and immediately used in
competition binding assays as described below.
Large unilamellar vesicles preparation
LUVs composed of PC (PC-LUVs) or PC and PS
(50:50 mol:mol, PC/PS-LUVs) were prepared by extru-
sion through polycarbonate membranes of 100 nm pore
diameter, employing mini extruder equipment (Avanti
Polar Lipids), as previously described [35]. They were
maintained at 4 °C under N2 atmosphere and imme-
diately used in competition binding assays as de-
scribed below.
Isolation of mouse peritoneal cells
Isolation of mouse inflammatory cells was achieved fol-
lowing a procedure previously described [36, 37]. Briefly,
C57BL/6J or B6.129S7-Ldlrtm1Her (LDLr−/−) mice were
injected with 100 μL of Freund’s incomplete adjuvant to
induce an appropriate recruitment of inflammatory cells
into the peritoneal cavity. After 48 h mice were eutha-
nized by cervical dislocation under anaesthesia and cells
were obtained by peritoneal washes using PBS contain-
ing 2 mM EDTA and 2 % (v/v) FS. Mouse peritoneal
cells were then immediately used in binding assays as
described below.
Cell culture
The human monocyte-like cell line THP-1 (American
Type Culture Collection, USA) was maintained in RPMI
1640 culture medium containing 10 mM HEPES, 1.5 g/L
sodium bicarbonate, 1 mM sodium pyruvate, 2 mM glu-
tamine, penicillin/streptomycin/amphotericin B (100
U/mL, 0.1 mg/mL, 250 ng/mL, respectively) and 10 %
(v/v) FS. Cells were maintained in a humidified 37 °C
incubator with 5 % (v/v) CO2 and subcultured every
3–4 days to maintain density between 0.2–1.0 × 106
cells/mL. For macrophage differentiation, cells were
stimulated with PMA (50 ng/mL) for 72 h. Character-
isation of PMA-differentiated macrophages was carried
out by flow cytometry using specific antibodies for
cell receptors in the conditions recommended by the
manufacturer (BD Bioscience). THP-1 monocytes were
CD14lowCD32highCD64high and they became CD14
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−CD64medCD32med after PMA-differentiation as expected
for macrophages. THP-1 monocytes and THP-1-
derived macrophages were used in binding assays as
described below.
Binding of biotinylated proteins to cells
Binding assays were performed by flow cytometry using
biotinylated proteins and mouse peritoneal cells, THP-1
monocytes or THP-1 derived macrophages. For THP-1
macrophages, cells were firstly detached using cold PBS
containing 1 mM EDTA. All incubations and washing
steps were carried out in binding buffer (BB, PBS con-
taining 1 % (v/v) FS and 0.1 % NaN3). Cells were dis-
pensed in 96-well conical bottom plates at 0.5, 0.75 or
1.0 × 106 cells/well for THP-1 monocytes, macrophages
and peritoneal cells respectively. Cells were incubated
for 1 h at 4 °C with increasing concentrations of the bio-
tinylated protein in duplicates or triplicates. After three
washing steps with BB, protein binding was detected by
incubation with an excess concentration of streptavidin-
FITC for 45 min at 4 °C. In parallel, cells were incubated
with biotinylated OVA for controlling unspecific bind-
ing. After washing, cells were examined using a FACS-
Calibur flow cytometer (BD Biosciences, USA) and data
was analysed using Cell Quest software or the FlowJo™
package. In the case of peritoneal cells, cells were co-
stained with anti-mouse F4/80 antibody conjugated to
phycoerythrin (or its corresponding isotype control)
which allow to analyse the binding to mouse peritoneal
monocytes and macrophages by gating on F4/80+ cells.
Lymphocytes were defined on the basis of their size (for-
ward scatter), cell complexity (side scatter) and stain for
F4/80 expression (negative cells). For comparison, the
binding of biotinylated proteins was expressed as bind-
ing index, which corresponds to the ratio of the fluores-
cence intensity (geometric mean) of the sample relative
to the control (cells incubated with BB).
Binding assays using the EB7 monoclonal antibody
Similar binding assays were performed using THP-1
monocytes and macrophages, and the EB7 mab for de-
veloping. Briefly, cells were incubated with unlabelled
native EgAgB, EgAgBPLD+, EgAgBPLD- or lipid-free
rEgAgB8/1 subunit for 1 h at 4 °C in duplicate or tripli-
cate. Protein binding was detected by incubation with
EB7 mab for 45 min at 4 °C, followed by incubation with
goat anti-mouse IgG/IgM conjugated to FITC (1/50) for
45 min at 4 °C. In parallel, controls were carried out by
adding BB instead of EgAgB, or mouse IgG1 kappa iso-
type control instead of EB7 mab. After washing, cells
were analysed by flow cytometry as stated above. The
binding of EgAgB to the cells was expressed as binding
index, as previously described.
Competition binding assays
Competition binding assays were performed by co-
incubating biotinylated and unlabelled EgAgB to exam-
ine binding specificity. All incubations were performed at
4 °C and using BB. For these experiments, we used THP-1
monocytes or macrophages, the minimum concentration
of biotinylated EgAgB needed for saturation, and a ratio of
unlabelled:biotinylated EgAgB ranging from 0.5:1 to 4:1.
Co-incubation using unlabelled OVA and biotinylated
EgAgB (in a mass ratio of 4:1, which corresponds to about
20-fold molar excess) was undertaken as a control. For
comparison similar competition assays were carried out
with unlabelled and biotinylated OVA. In addition, com-
petition binding assays were performed using LUVs,
plasma lipoproteins (HDL and LDL) and ligands of lipo-
protein receptors (lactoferrin and polyinosinic acid) in an
excess concentration as indicated. In the latter competi-
tion assays cells were not co-incubated with EgAgB and
the competitor to prevent possible interactions between
EgAgB particles and LUVs or lipoproteins; instead, after a
pre-incubation with the competitor (30 min), cells were
centrifuged and subsequently re-suspended in BB contain-
ing the biotinylated EgAgB. All assays were carried out in
duplicate or triplicate.
Cytokine secretion assays
For cytokine secretion assays, THP-1 monocytes (0.5 ×
106 cells/well) were differentiated with PMA for 72 h
and then cultured in medium without PMA for 24 h.
The resultant macrophages were stimulated with PMA
(50 ng/mL) or LPS (0.1 μg/mL) in the absence or pres-
ence of increasing concentrations of immunopurified
EgAgB (1, 10 or 20 μg/mL) for 12 h at 37 °C with 5 %
(v/v) CO2. In parallel cells were incubated with PBSEB or
immunopurified EgAgB (20 μg/mL) as controls. The
levels of IL-1β, TNFα and IL-10 in culture supernatants
were determined by capture ELISA employing OptEIA
kits (BD Biosciences), according to the manufacturer’s
instructions.
Arginase activity assay
Arginase activity was evaluated in macrophage cultures
employing the method described by Corraliza and col-
laborators [38]. Briefly, bone marrow-derived macro-
phages (BMDM) were generated by differentiation of
bone marrow precursors from 8 to 10 week old BALB/c
mice for 7 days in the presence of conditioned medium
of the M-CSF-secreting L929 cell line. BMDM were
cultured in the presence of immunopurified EgAgB
(0.2–20 μg/mL), murine IL-4 (2.5 ng/ml, as a control of
alternative activation) or PBSEB, and after 24 h they were
lysed with 0.1 % Triton X-100. Cells were scraped into
10 mM MnCl2, 50 mM Tris–HCl, pH 7.5 and heated to
56 °C for 10 min to activate arginase-I. Substrate
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hydrolysis was performed by adding 0.5 M L-arginine,
pH 9.7 to the cell lysate followed by 60 min incubation
at 37 °C. The reaction was stopped by adding an acid
mixture containing H2SO4, H3PO4 and H2O (1:3:7).
After adding α-isonitrosopropriophenone, samples were
heated to 110 °C for 30 min, and urea content was then
measured spectrophotometrically at 540 nm. Enzymatic
activity (U) was determined as μmoles of urea generated
per minute, employing a urea calibration curve. Arginase
activity was then expressed as mU per million of
BMDM. In parallel, nitrite levels in BMDM culture su-
pernatants were determined employing Griess assay ac-
cording to Green and collaborators [39].
Statistical analysis
For all studies, data were obtained from at least three in-
dependent experiments and expressed as means ± stand-
ard error of the mean (SEM). Most statistical analyses
were undertaken employing Graph Prism software. In
most studies one-way analysis of variance (ANOVA)
followed by the indicated post hoc test (Tukey’s or Dun-
nett’s test) was used to evaluate the binding ability of
EgAgB (native, the recombinant subunits or PLD-treated
EgAgB) to cells. Two-way ANOVA followed by Bonfer-
oni post hoc test was used for comparing the binding
index exhibited by EgAgB at different doses. For compe-
tition assays one way ANOVA and restricted maximum
likelihood (REML) test were used, employing JMP soft-
ware. Significance was defined as p < 0.05 and was indi-
cated in each figure.
Results and discussion
Infertile bovine cysts constitute the main parasite mater-
ial to which we have access in our country. Despite
EgAgB being the most abundant parasite component of
HF, we only recovered between 1.5 and 2.5 mg of EgAgB
per L of infertile HF. Studies described in this work re-
quired preparation of five independent batches of native
EgAgB, each batch from a representative number of in-
dividual cysts (at least 10 cysts, 15 cysts on average).
Due to the high diversity of EgAgB family, we firstly
characterised the protein moiety of native EgAgB, in
order to know which EgAgB8 apolipoproteins are rele-
vant for binding studies. Characterisation by LC-MS/MS
analysis of these batches demonstrated the presence of
EgAgB8/1 to EgAgB8/5 (Table 1), where EgAgB8/1 was
the predominant subunit according to the iBAQ param-
eter, reaching a relative abundance of 96 %. Interestingly,
we found similar results when the protein composition
of native EgAgB present in fertile HF was analysed by
LC-MS/MS; although all EgAgB8 subunits were present,
EgAgB8/1 was over-represented (Ana Maite Folle, un-
published observations). Taken together, these results
support that EgAgB8/1 constitutes the bulk of the apoli-
poprotein component found in EgAgB derived from HF
and it is mainly synthesised by the GL.
Native EgAgB binds to F4/80+ mouse peritoneal cells
As noted above, EgAgB function may be linked to the
parasite adaptation response to host environment, by
mediating lipid mobilisation from host to parasite tissues
[21, 23] and/or by contributing to modulate the effector
mechanisms displayed by immune cells [29–32]. Because
evidence of EgAgB effects on myeloid cells exists, we ini-
tially attempted to examine EgAgB interactions with
inflammatory cells. For that purpose, we performed
fluorescence binding assays employing mouse peritoneal
cells, recovered after adjuvant-induced acute inflamma-
tion, biotinylated EgAgB and streptavidin-FITC for de-
velopment. Employing biotinylated EgAgB offered the
advantage to examine the binding of EgAgB independ-
ently of the apolipoprotein composition of individual








EgAgB8/1 Q5EKQ4 7589.9 8.31 29.7 (53.5) 28.1 DDGLTSTSR, DPLGQKVVDLLK, DPLGQKVVDLLKELEEVFQLLR, ELEEVFQLLR,
ELEEVFQLLRK, VVDLLKELEEVFQLLR, VVDLLKELEEVFQLLRK, YFFERDPLGQK
Q9UA06a 7555.9 8.31
EgAgB8/2 Q5EKP1 7906.2 9.42 21.1 (37.7) 19.5 AHMGQVVK, AHMGQVVKKDFFRNDPLGQR, LVALGNDLTAICQK,
NDPLGQR, NLVEEKDDDSK, YVKNLVEEK, YVKNLVEEKDDDSK
Q27275b 8193.5 9.37
EgAgB8/3 Q95NW6c 7858.2 8.02 24.0 (33.9) 22.4 DDDDDEVTK, DVASVCEMVR, HFFQSDPLGK, HFFQSDPLGKK
A0A068X006–1 6712.8 6.78
EgAgB8/4 Q6Q0H5 8353.66 6.20 24.1 (27.3) 22.6 DFFRSDPLGQR, DLLEEEEEEDDSK, DLTAICQK, YVKDLLEEEEEEDDSK
EgAgB8/5 Q5EKP9 7657.07 9.56 21.0 (14.7) 19.4 EVASVCQMVR
The following proteins (Uniprot accession numbers) generate identical mature products to that indicated with a superscript letter: a U6JQF4 and Q5S577,
b Q5EKN4, C1KBK4, Q6Q0H3 and Q6Q0I3, c Q5EKQ8, Q5EKR1, Q5EKR3 and Q95W92
Molecular mass and isoelectric point (pI) of mature proteins were calculated using the “compute pI/MW” Expasy tool (http://web.expasy.org/compute_pi/)
Intensity values correspond to log2 of summed XIC (extracted ion current) of all isotope clusters associated to the corresponded protein and are given as median
of quintuplicates. The iBAQ values were also log2-transformed and their relative standard deviation was ≤ 1.1 %
Coverage values correspond to the percentage of the protein sequence that is covered by the identified peptides
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particles, since all EgAgB8 isoforms contain various ly-
sine residues [22] to allow easy protein biotinylation. All
incubations were performed at 4 °C in the presence of
NaN3 to avoid EgAgB endocytosis. We used the binding
index, defined as the increment of the fluorescence rela-
tive to the control, in order to compare the binding ac-
tivity of EgAgB and OVA. We found that EgAgB binding
index to inflammatory F4/80+ cells (including mainly
macrophages, but also inflammatory monocytes) was
more than 20-fold higher than that observed for OVA
used as control, and this difference was statistically
significant (Fig. 1). Furthermore, EgAgB binding to
inflammatory F4/80+ cells was significantly higher than
that to inflammatory lymphocytes. Altogether, these re-
sults indicated that monocytes and macrophages re-
cruited in an inflammatory site are able to interact with
native EgAgB (Fig. 1).
Native EgAgB binds to THP-1 monocytes and
macrophages
Since E. granulosus hydatid cyst is extremely well
adapted to host inflammation [40], resident immune
cells in the cyst vicinity may not be exposed to a strong
pro-inflammatory environment once the parasite has
Fig. 1 Binding of native EgAgB to mouse inflammatory cells. Binding of native EgAgB to mouse inflammatory cells was evaluated using peritoneal
inflammatory cells and biotinylated EgAgB (20, 50 and 100 μg/mL). Biotinylated OVA was used as a control. Protein binding was detected by
incubation with an excess concentration of streptavidin-FITC. Macrophages and monocytes were selected by co-staining with anti-F4/80 antibody
conjugated to phycoerythrin. Lymphocytes were identified on the basis of their size (FSC), complexity (SSC) and negative stain for F4/80. a Histograms
with the distribution of cell population as function of FITC fluorescence for controls (grey) and EgAgB-treated cells (red). Histograms are representative
of three independent experiments for monocytes/macrophages (F4/80+) and lymphocytes (F4/80−). b EgAgB binding to monocytes/macrophages or
lymphocytes are shown as binding index (increment of the fluorescence relative to the control with BB), corresponding to the mean values ± SEM of
three independent experiments. Binding of OVA (grey) and native EgAgB (red) is shown for monocytes/macrophages (empty bars) and for
lymphocytes (filled bars). Asterisks (*) denote significant differences with respect to the control (one way ANOVA followed by Dunnett’s post-test,
p < 0.05), while number signs (#) denotes significant differences when comparing the binding to monocytes/macrophage to that to lymphocytes
(one-way ANOVA analysis, followed by Tukey’s post-test (p < 0.05)
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been established. Thus we studied the EgAgB binding
activity to non-activated macrophages and monocytes
using similar fluorescence binding assays and the
monocyte-like THP-1 cell line of human origin. When
comparing the binding index at the same protein dose,
and in a wide range of ligand concentrations (20 –
350 μg/ml), we found that biotinylated EgAgB showed a
higher binding index to THP-1 monocytes and macro-
phages than biotinylated OVA (Fig. 2a and b, respect-
ively). In addition, when the fluorescence intensity was
plotted vs. EgAgB concentration saturation curves were
obtained (Fig. 2c and d), suggesting that EgAgB binding
to monocytes and macrophages involved specific inter-
actions. The apparent dissociation constant (Kd) deter-
mined from both curves was similar (83 ± 5 and 79 ±
5 μg/ml for monocytes and macrophages, respectively),
which corresponds to ~3 ×10−7 M, considering an aver-
age molecular mass of 230 kDa for the native lipoprotein
[21]. In comparison, in the conditions of our assay OVA
showed a lower affinity for THP-1 cells (with a Kd of
175 ± 25 and 327 ± 92 μg/ml for monocytes and macro-
phages, respectively), corresponding to ~10−6 M, an
order of magnitude lower than for EgAgB. Taken to-
gether, these results showed that EgAgB binds specific-
ally to THP-1 monocytes and macrophages, with a Kd
~10−7 M. This value likely represents an average of the
affinities of EgAgB, since the native lipoprotein com-
prises a heterogeneous mixture of particles, with mo-
lecular masses between 400 and 200 kDa [21]. As an
alternative to using biotinylated ligand, EgAgB binding
Fig. 2 Binding of native EgAgB to THP-1 derived monocytes and macrophages. Binding of native EgAgB to THP-1 monocytes and macrophages
was evaluated using biotinylated EgAgB or biotinylated OVA as control (20–350 μg/ml). In (a) and (b) Binding indexes of OVA (grey) or native
EgAgB (red) for monocytes and macrophages, respectively; data are expressed as mean values ± SEM of triplicates. Asterisks (*) denote significant
differences in binding indexes of native EgAgB with respect to the control (two-way ANOVA followed by Bonferroni’s post-test, p < 0.05). (c), (d)
Titration curves obtained for OVA (▲) or EgAgB (●) binding to monocytes or macrophages, respectively. Several fitting models of Graph Prism
software were tested and the “binding saturation with one side-specific binding” model showed the best R2 (0.992). The solid line corresponds to
the theoretical binding curve obtained for each protein. One representative experiment of three is shown in each panel
Silva-Álvarez et al. Parasites & Vectors  (2016) 9:69 Page 8 of 17
to monocytes and macrophages was examined by devel-
oping the interaction with an anti-EgAgB monoclonal
antibody (EB7 mab), which recognizes EgAgB8/1 -the
predominant subunit found in the native antigen-, but
not EgAgB8/2 [13] or EgAgB8/3 (Additional file 2). No
data is available in relation to the recognition of EB7
mab for EgAgB8/4, but it is unlikely since EgAgB8/4 is
more similar to EgAgB8/2 than to EgAgB8/1 [18]. Using
this approach, we found that the binding index was sig-
nificantly higher for native EgAgB than for the control
(mouse IgG) and increased in a dose-dependent manner
(Additional file 3). Overall, results show that monocytes
and macrophages are able to bind native EgAgB, in par-
ticular those lipoprotein particles containing EgAgB8/1.
In order to confirm a specific interaction of monocytes
and macrophages with EgAgB, we performed a competi-
tion assay in which cells were co-incubated with bio-
tinylated and unlabelled EgAgB. For this assay we used
the minimum concentration of biotinylated EgAgB
needed to achieve saturation and employed a ratio ran-
ging from 0.5:1 to 4:1 of unlabelled:biotinylated protein.
In parallel, cells were co-incubated with biotinylated
EgAgB and OVA as a control. We found that unlabelled
EgAgB was able to compete with biotinylated EgAgB for
the binding of monocytes and macrophages (Fig. 3a and
b, respectively). In contrast, the binding of biotinylated
OVA was not inhibited by unlabelled OVA. Moreover,
no inhibition of EgAgB binding to monocytes and mac-
rophages was observed when an excess of OVA was used
for competition (Fig. 3a and b). Overall, these results
indicated that THP-1 monocytes and macrophages are
able to specifically bind native EgAgB, suggesting that
these cells possess at least one surface receptor for
EgAgB.
EgAgB apolipoproteins directly contribute to EgAgB binding
to cells
Native EgAgB is a complex lipoprotein particle com-
posed of around a dozen EgAgB8 subunits, which are
likely exposed at the outer hydrophilic surface of the
lipoprotein [21]. The involvement of these subunits in
EgAgB binding to monocytes and macrophages was
examined using biotinylated lipid-free rEgAgB8/1,
rEgAgB8/2 and rEgAgB8/3 subunits. For that purpose,
rEgAgB8 subunits were labelled with biotin in conditions
to generate a maximum of six biotinylated lysines resi-
dues per molecule, attempting to avoid a significant per-
turbation of the protein structure. Since the yield of
rEgAgB8/1 expression and delipidation procedures was
much lower in comparison with that obtained for
rEgAgB8/2 and rEgAgB8/3, some assays were carried
out only with the latter subunits. It is relevant here that
from the amino acid sequence, EgAgB8/3 is more similar
to EgAgB8/1 than to EgAgB8/2 [18].
When analysing the binding of rEgAgB8 subunits to
peritoneal F4/80+ macrophages we found that rEgAgB8/
3 behaved similarly to native EgAgB; rEgAgB8/3 binding
Fig. 3 Competition binding assays for studying binding specificity.
In these assays the binding of biotinylated EgAgB (in a fixed
concentration 250 μg/ml) was competed out by the unlabelled
lipoprotein (at concentrations between 125 and 1000 μg/ml) or OVA
(1000 μg/ml) as a control (red bars). In parallel, similar competition
assays were carried out using biotinylated OVA (grey bars). a Assays
for THP-1 monocytes. b Assays for THP-1 macrophages. Results are
expressed as binding index, and correspond to mean values ± SEM
of triplicates. Asterisks (*) indicate significant differences with respect
to the binding of biotinylated OVA used as a control, while number
signs (#) indicate significant differences with respect to biotinylated
EgAgB incubated in the absence of the unlabelled lipoprotein
(one-way ANOVA followed by Tukey’s post-test, p < 0.05). One
representative experiment of two is shown in each panel
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index increased in a dose-dependent manner, being sig-
nificantly higher than that for OVA (Fig. 4a). Moreover,
rEgAgB8/3 binding to macrophages was significantly
higher than to lymphocytes (Fig. 4a). On the other hand,
binding of rEgAgB8/2 to macrophages was not observed;
the binding index showed a trend to increase in a dose
dependent manner, but this trend did not reach statis-
tical significance (Fig. 4a). The different behaviour be-
tween rEgAgB8/2 and rEgAgB8/3 was also found when
we used THP-1 cells for binding studies (Fig. 4b and c).
rEgAgB8/3, but also rEgAgB8/1 were capable of binding
to both monocytes and macrophages in a dose
dependent manner. In contrast, rEgAgB8/2 did not bind
to monocytes and showed a slight binding to macro-
phages. Taken into account that the extent of biotinyl-
ation of all subunits was similar (even a bit lower for
rEgAgB8/3, Additional file 1), these results show that
rEgAgB8/2 has a lower ability to interact with mono-
cytes and macrophages than rEgAgB8/1 and EgAgB8/3,
supporting the existence of differences in the biological
properties of EgAgB subfamilies. However, it cannot be
discarded that biotinylation would affect the binding
properties of rEgAgB8/2 in a greater extent than those
of EgAgB8/1 and EgAgB8/3. The capacity of rEgAgB8/1
to bind to THP-1 monocytes and macrophages was con-
firmed using EB7 mab to analyse the interaction
Fig. 4 Analysis of the ability of monocytes and macrophages to bind rEgAgB8 subunits. Binding assays were performed using biotinylated lipid-
free rEgAgB8/1, rEgAgB8/2 and rEgAgB8/3. a Binding index of rEgAgB8 subunits (20, 50 and 100 μg/ml) to mouse peritoneal inflammatory cells is
shown. Data are expressed as mean ± SEM of three independent experiments. Asterisks (*) indicate significant differences with respect to the
control (OVA) according to the analysis by one-way ANOVA followed by Dunnett’s post-test (p < 0.05). Number signs (#) denotes significant
differences between binding to monocytes/macrophage and binding to lymphocytes, according to one-way ANOVA analysis, followed by Tukey’s
post-test (p < 0.05). (b), (c) Binding indexes of rEgAgB8 subunits to THP-1 derived monocytes and macrophages, respectively. Data are expressed
as mean ± SEM of three independent experiments. Asterisks (*) indicate significant differences with respect to the control (OVA) (one-way ANOVA
followed by Dunnett’s post-test, p < 0.05)
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(Additional file 4). The observed similarities and differ-
ences in cell interaction among EgAgB subunits are in
accordance with the degree of identity between members
of EgAgB family; as stated above EgAgB8/1 and
EgAgB8/3 are more similar to each other than to
EgAgB8/2. Taking into account that EgAgB8/1 was the
predominant apolipoprotein found in the native EgAgB
present in the HF, our results indicate that monocytes
and macrophages may be mainly capable of recognising
native EgAgB through EgAgB8/1. EgAgB8/3 might con-
tribute to this recognition as well; although this subunit
is poorly represented in the native EgAgB purified from
HF, we cannot rule out that the composition of EgAgB
released from the cyst towards host tissues may vary at
distinct time points during infection or between different
intermediate hosts.
EgAgB phospholipids provide an adequate environment
for EgAgB binding to cells
In accordance with the structural organisation proposed
for native EgAgB, phospholipids may form the outer
layer of the lipoprotein particle in which EgAgB subunits
are embedded. Therefore, phospholipids may play a rele-
vant role in EgAgB binding to target cells by contribut-
ing to the exposure of apolipoprotein domains towards
the hydrophilic milieu or by making direct contacts with
cell receptors. To analyse the involvement of EgAgB
phospholipids in the binding of the native lipoprotein to
monocytes and macrophages, we treated EgAgB with
PLD to remove the polar head group from phospho-
lipids, yielding phosphatidic acid. PLD-treated EgAgB
was then repurified by ultracentrifugation in a KBr gra-
dient to ensure the recovery of the whole lipoprotein
particle after treatment. Analysis by HPTLC of the lipid
moiety of EgAgBPLD+ showed that PLD-treatment
worked efficiently since it caused a strong alteration in
the phospholipid composition of EgAgB. All phospho-
lipid classes present in the mock control (EgAgBPLD-)
disappeared after PLD treatment being substituted by a
unique component that exhibited a migration pattern
compatible with phosphatidic acid in the assayed chro-
matographic conditions (Fig. 5a, dotted black arrow)
[41]. The analysis of EgAgBPLD- and EgAgBPLD+ binding
to THP-1 monocytes and macrophages revealed signifi-
cant differences between these lipoprotein particles.
EgAgBPLD- bound to monocytes and macrophages to a
similar extent to native EgAgB, whereas EgAgBPLD+ lost
around 80 % of the binding capacity (Fig. 5b and c). It
cannot be excluded that this detrimental effect caused
by PLD treatment was a consequence of the negative
charge generated by the formation of phosphatidic acid.
Therefore, our results suggest that phospholipids may be
directly involved in EgAgB-cell interactions or they may
contribute indirectly, by generating an adequate
framework for the recognition of EgAgB8 subunits in
the surface of the lipoprotein particle. In order to evalu-
ate whether phospholipids participate directly in EgAgB
binding to cells, we performed competition assays
employing PC-LUVs, which may model the PC
enriched-phospholipid layer exposed on EgAgB, and PC/
PS-LUVs for comparison. We found that pre-incubation
of monocytes with PC/PS-LUVs, using a mass ratio of
5:1 LUVs:EgAgB, did not alter EgAgB binding to cells.
PC-LUVs however caused a slight reduction (about
10 %) in EgAgB binding (Fig. 5d), which was not com-
parable to that caused by PLD treatment. These results
suggest that EgAgB binding to monocytes may not be
dependent on cell interactions with phospholipids ex-
posed at the surface of EgAgB particle. On the other
hand, the fact that PC-LUVs, but not PC/PS-LUVs
caused a modest, but significant inhibition on EgAgB
binding, suggests that electrostatic forces may play a role
in EgAgB-cell interactions.
In summary, in accordance with the results described
above, monocytes and macrophages are able to recog-
nise specifically native EgAgB, through motifs belonging
to EgAgB8 apolipoproteins rather than to the lipid com-
ponents. In particular, the binding activity was found in
EgAgB8/1, which is the most abundant apolipoprotein
of the native EgAgB present in HF. Electrostatic interac-
tions between EgAgB8 subunits and phospholipids may
contribute to an adequate assembly and/or exposure of
EgAgB subunits in the particle surface, which agrees
with the predicted formation of negative and positive
charge regions in all apolipoproteins by in silico struc-
ture modelling [23]. On the other hand, the fact that the
binding activity motifs seem to be present in rEgAgB8
apolipoproteins suggests that the intact lipoprotein
structure is not essential for cell binding. This might ex-
plain why denatured EgAgB preparations showed modu-
latory effects on immune cells [30, 31]. In any case,
these protein motifs seem to be resistant to high
temperature, SDS and electroelution. Nevertheless, the
biological effects triggered by these motifs on immune
cells may be partially different to that caused by the na-
tive EgAgB, as the latter might bind to a different set of
cell receptors, imprinting different signals into the cell.
Lipoprotein receptors are likely involved in EgAgB
binding to cells
Since EgAgB lipoprotein share physicochemical proper-
ties with plasma lipoproteins, particularly with HDL par-
ticles [21], we performed competition experiments with
HDL and LDL in order to assess whether lipoprotein re-
ceptors are involved in EgAgB-cell interactions. For
these experiments, THP-1 monocytes were pre-incubated
with HDL and LDL, centrifuged and then incubated with
biotinylated EgAgB. We did not undertake a co-
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Fig. 5 Contribution of phospholipid moiety in EgAgB binding to monocytes and macrophages. EgAgB was treated with PLD to remove the polar
head group from phospholipids. a HPTLC analysis of the lipid fractions extracted from EgAgBPLD- and EgAgBPLD+. Lipid bands were visualised
using iodine vapour and identified by comparison with the standards (STD). The solid arrow indicates the band corresponding to phosphatidylcholine,
whereas the dotted arrow indicates the band corresponding to phosphatidic acid. (b), (c) Binding of EgAgBPLD- and EgAgBPLD+ to monocytes and
macrophages, respectively. Binding was detected employing EB7 mab followed by incubation with anti-IgG/IgM-FITC. Results are expressed as
percentage of binding (% binding), where 100 % corresponds to the binding of native EgAgB without any treatment. Data are expressed as mean ±
SEM of three independent experiments. Asterisks (*) indicate significant differences with respect to the control (EgAgBPLD-) according to one-way
ANOVA analysis followed by Dunnett’s post-test (p < 0.05). d Competition binding assays employing PC-LUVs and PC/PS-LUVs. Results are expressed as
percentage of binding (% binding), where 100 % corresponds to the binding of native EgAgB in the absence of LUVs. Data are expressed as mean ±
SEM of three independent experiments. Asterisks (*) indicate significant differences with respect to the 100 % of binding (without LUVs.) in accordance
with one-way ANOVA analysis followed by Dunnett’s post-test (p < 0.05). Abbreviations: Cho (cholesterol); FA (free fatty acids); DAG (diacylglycerols); SE
(sterol esters); TAG (triacylglycerols); PC (phosphatidylcholine); CL (cardiolipin) and PE (phsophatidylethanolamine)
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incubation of EgAgB with HDL or LDL to avoid putative
EgAgB-lipoprotein interactions that may reduce EgAgB
binding without the involvement of lipoprotein receptors.
We found that both HDL and LDL partially inhibited
binding of EgAgB to monocytes; they caused a modest,
but statistically significant inhibition (Fig. 6). These results
suggest that EgAgB binding to monocytes and macro-
phages is at least partially mediated by receptors shared
with LDL and HDL.
Although EgAgB8 apolipoproteins do not have similar-
ity at the amino acid sequence level with HDL and/or
LDL apolipoprotein components, they exhibit some bio-
chemical features similar to exchangeable plasma apoli-
poproteins, which are components of both HDL and
LDL [42, 43]. Indeed, exchangeable apolipoproteins in-
clude small, α-helix rich proteins (some of them less
than 10 kDa in mass) [42], and, lipid-free EgAgB apoli-
poproteins have substantial amounts (about 40 %) of α-
helical structure [20], which increases when bound to
lipids (about 65 % for the native lipoprotein) [44]. Fur-
thermore, in silico analysis of the secondary structure of
EgAgB8/1, EgAgB8/2 and EgAgB8/3 [22, 44] suggests
that these apolipoproteins would adopt amphipathic α-
helical structures, a feature associated with the ex-
changeability of apolipoproteins such as Apo AI and
Apo E (reviewed by Jonas and Phillips, [42]). Similarities
in the distribution of polar and/or charged amino acids
between EgAgB8 and exchangeable apolipoproteins
present in HDL and LDL might explain why these evolu-
tionarily distant lipoproteins share receptors in mono-
cyte and macrophages. On the other hand, there is a
wide range of receptors in innate immune cells involved
in lipoprotein recognition, including families exhibiting
a relatively promiscuous ligand specificity, such as the
LDL-receptor family and scavenger receptors [45, 46].
Since EgAgB8 subunits seem to adopt tertiary structures
in which positive and negative charges are grouped [23],
we explored the involvement of lipoprotein receptors
containing domains with affinity for positively-charged
(LDL receptor related protein 1 [LRP1] and LDLr [45])
or negatively-charged (class A scavenger receptor [SR-A]
[45, 46]) motifs. For that purpose we carried out com-
petitive binding assays using an excess of lactoferrin and
polyinosinic acid, which are high-affinity ligands for
LRP-1 and SR-A respectively. As shown in Additional
file 5, we found no evidence of the involvement of any
of these receptors. Furthermore, using monocytes and
macrophages from LDLr-deficient mice, we explored the
involvement of LDLr in the binding of native EgAgB. No
evidence was found as inflammatory peritoneal F4/80+
cells recovered from LDLr-deficient mice exhibited simi-
lar EgAgB binding activity to those from controls (also
shown in Additional file 5). Further studies for identify-
ing EgAgB receptor(s) are needed. This identification to-
gether with the characterisation of the signalling
pathway triggered by EgAgB recognition are of foremost
importance to elucidate the role played by EgAgB in
parasite biology.
Exposure to native EgAgB affects the functional
properties of macrophages
Studies on macrophage functional properties were per-
formed using immunopurified EgAgB to eliminate trace
levels of contaminants, particularly environmental pyro-
gens. The binding capacity of immunopurified EgAgB to
monocytes and macrophages was similar to that ob-
served for EgAgB preparations obtained by ultracentrifu-
gation (Additional file 6). THP-1 macrophages were
stimulated with PMA or LPS in the presence or absence
of immunopurified EgAgB to assess whether EgAgB has
the capacity to modulate inflammatory macrophage re-
sponses. Exposure to EgAgB on its own did not induce
secretion of IL-1β or TNFα (Fig. 7). This result indicates
that EgAgB does not activate macrophages in a similar
way than PMA and LPS do. Furthermore, it confirmed
that the EgAgB preparation exclude contamination by
pyrogens. The presence of EgAgB during PMA or LPS
stimulation caused a dose–response inhibition of IL-1β
or TNFα secretion (Fig. 7), but no effects were observed
on IL-10 production (Additional file 7). These results
suggest that native EgAgB is able to trigger IL-10
independent-signalling pathways that control PKC and
TLR4-mediated inflammatory responses. Inhibition of
IL-1β or TNFα secretion by immunopurified EgAgB
agrees with a previous report in which EgAgB was found
Fig. 6 Participation of plasma lipoprotein receptors in EgAgB binding
to monocytes. THP-1 monocytes were pre-incubated with HDL and
LDL (500 μg/ml), centrifuged and then incubated with biotinylated
EgAgB (20, 50 100 and 250 μg/ml). Results are expressed as binding
indexes and correspond to mean values ± SEM of three independent
experiments. Asterisks (*) indicate significant differences with respect to
the control incubated without lipoproteins, according to analysis by
REML test employing JMP software
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to modulate the differentiation as well as the LPS
induced-activation of immature dendritic cells [31]. In
contrast with this report, in macrophages IL-10 secre-
tion was not affected by exposure to EgAgB, suggest-
ing signalling differences between cell types and/or
EgAgB preparations. Activation of macrophages to an
alternative-activated phenotype characterised by ex-
pression of arginase-I, was also investigated. For that
purpose, BMDM were used since THP-1 macrophages
are not appropriate to analyse arginase activity.
BMDM were incubated with different doses of EgAgB
for 24 h and arginase activity was determined in
cell lysates. Since nitric oxide synthase 2 (NOS2)
competes with arginase-I for their common substrate
L-arginine, we examined NOS2 induction by measur-
ing the production of nitrite in cell supernatants. In
line with results obtained for cytokine secretion,
EgAgB exposure to its own did not generate detect-
able levels of nitrite (lower than 3.125 μM), support-
ing that inflammatory pathways linked to NOS2
induction were not stimulated by EgAgB. On the
other hand, in comparison with IL-4, exposure to
EgAgB induced a slight increase in arginase activity
(Additional file 8), suggesting that EgAgB is not a po-
tent inducer of the alternative activation pathway in
macrophages.
Fig. 7 Effects of EgAgB on pro-inflammatory cytokine production by macrophages. THP-1 macrophages were stimulated with PMA (50 ng/ml) or
LPS (0.1 ng/ml) for 12 h in the absence or presence of increasing concentrations of EgAgB. Secretion of IL-1β (a, b) and TNFα (c, d) were determined
by ELISA in cell culture supernatant. IL-1β or TNFα levels are expressed as the fold-increase related to the basal secretion (normalised against the
medium condition). Results correspond to mean values ± SEM of at least two independent experiments. Asterisks (*) indicate significant differences
with respect to PMA or LPS-stimulated macrophages according to one-way ANOVA analysis followed by Tukey’s post-test (p < 0.05)
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Conclusions
The results we present in this work support the concept
that once EgAgB reaches host tissues it may bind to tis-
sue resident macrophages and inflammatory monocytes
recruited during infection, through cell receptors likely
involved in the recognition of plasma lipoproteins.
EgAgB signalling through these receptors seems to in-
duce a non-inflammatory phenotype in macrophages. In
fact, this signalling could limit TLR4-mediated cytokine
production that may occur during cyst growth, as a re-
sult of degradation of extracellular matrix [47]. Further-
more, it cannot be ruled out that EgAgB signalling
would contribute to drive macrophage differentiation to-
wards an alternative activation-like phenotype, which is
consistent with the Th2-regulated immune response
found in helminth infections, including echinococossis
[40, 48]. Identification of cell receptor(s) and signalling
pathways involved in EgAgB recognition by innate cells
will be of foremost importance for understanding EgAgB
role in parasite adaptation to host. Regarding EgAgB cell
receptor(s), they likely recognise electrostatic motifs of
EgAgB8/3 and EgAgB8/1, the latter constitutes the pre-
dominant protein component of native EgAgB present
in HF. The fact that EgAgB cell receptors would also
bind host HDL and LDL, together with the non-
inflammatory phenotype observed after macrophage ex-
posure to EgAgB, suggest a cross-talk between metabolic
and inflammatory pathways [49], which requires further
investigation.
Additional files
Additional file 1: Comparison of the extent of biotinylation
obtained for native EgAgB, rEgAgB8 subunits and OVA. Proteins
were adsorbed on ELISA microplates in a wide range of concentrations
and the presence of biotin was determined using streptavidin-peroxidase
and TMB/H2O2 for development. The absorbance at 450 nm was plotted
vs. the protein concentration. (A) Comparison of the extent of biotinylation
between OVA and native EgAgB; data are expressed as the mean values ±
SEM of three analytical replicates B) Comparison of the extent of
biotinylation between rEgAgB8 subunits; data are expressed as the
mean values ± SEM of three analytical replicates. All preparations of
biotinylated native EgAgB used in this work were controlled in
respect to a preparation of OVA biotinylated in parallel. (TIF 6094 kb)
Additional file 2: Analysis of the ability of EB7 mab to recognize
rEgAgB8 subunits. EB7 rEgAgB8/1, rEgAgB8/2 and rEgAgB8/3 were
adsorbed on ELISA microplates to assess by ELISA the ability of Mab EB7
to recognize them. The binding of mab EB7 was developed using a
peroxidase conjugated anti-mouse IgG followed by TMB/H2O2. The
absorbance at 450 nm was plotted vs. the protein concentration. Data
correspond to mean values ± SEM of analytical triplicates. As observed in
the plot, mab EB7 recognises only EgAgB8/1. (TIF 62 kb)
Additional file 3: Binding of native EgAgB to THP-1 derived
monocytes and macrophages employing EB7 mab. Binding of native
EgAgB to THP-1 derived monocytes and macrophages was analysed
employing EB7 mab followed by incubation with goat anti-mouse IgG/
IgM antibody conjugated to FITC. As control, cells were incubated with
binding buffer instead of native EgAgB (PBS), without adding EB7 mab
(w/EB7) or using mouse IgG1 kappa isotype control instead of EB7 mab
(IC). In left panels figure shows the histograms with the distribution of
cell population as function of FITC fluorescence for controls (grey)
and EgAgB-treated cells (red). Histograms are representative of four
independent experiments for each cell type. In right panels binding
indexes were plotted vs. native EgAgB concentrations (1, 5 and
10 μg/ml) for monocytes (upper panels) and macrophages (bottom
panels). Data are expressed as mean ± SEM of four independent experiments.
Asterisks (*) indicate significant differences with respect to the control with
BB according to the analysis by t-test (p < 0.05), while number signs
(#) indicate significant differences in the binding indexes obtained at
1 and 10 μg/ml native EgAgB (one-way ANOVA followed by Tukey’s
post-test, p < 0.05). (TIF 11902 kb)
Additional file 4: Binding of recombinant EgAgB8/1 to THP-1
derived monocytes and macrophages employing EB7 mab. Binding
of rEgAgB8/1 to THP-1 derived monocytes and macrophages was analysed
employing EB7 mab followed by incubation with goat anti-mouse IgG/IgM
antibody conjugated to FITC. As control, cells were incubated with binding
buffer instead of native EgAgB (PBS), or in the absence of EB7 mab (w/EB7),
or using mouse IgG1 kappa isotype control instead of EB7 mab (IC).
Histograms (cell numbers vs. FITC fluorescence) corresponding to
control (grey) and rEgAgB8/1-treated cells (blue) are shown on the
left; they are representative of three independent experiments for
each cell type. On the right, the binding indexes were plotted vs.
rEgAgB8/1 concentration for monocytes (upper panel) and macrophages
(bottom panel). Data are expressed as mean ± SEM of three independent
experiments. Asterisks (*) indicate significant differences with respect to the
control (PBS) according to the analysis by t-test (p < 0.05), while number
signs (#) indicate significant differences in the binding indexes obtained at
different native EgAgB concentrations (one-way ANOVA followed by Tukey’s
post-test, p < 0.05). (TIF 12381 kb)
Additional file 5: Involvement of plasma lipoprotein receptors in
EgAgB binding to monocytes and macrophages. (A) Cells were
pre-incubated with ligands of LRP1 and SR-A receptors (lactoferrin and
poly-inosinic acid [poli-I], respectively), centrifuged and then incubated with
EgAgB in a fixed concentration (100 μg/ml). As control, BSA was used
at the maximum lactoferrin and poli-I concentration employed. The
binding index is expressed as mean ± SEM of analytical triplicates. (B)
Binding analysis of native EgAgB to monocytes/macrophages F4/80
+isolated from control (WT, empty bars) or LDLr−/− mice (filled bars). Statis-
tical analysis was undertaken by one-way ANOVA followed by Tukey’s post-
test, no significant differences were observed. One representative experi-
ment of two is shown in each panel. (TIF 302 kb)
Additional file 6: Binding of immunopurified EgAgB to THP-1
derived monocytes and macrophages employing EB7 mab. Binding
of immunopurified EgAgB to THP-1 derived monocytes and macro-
phages was analysed employing EB7 mab followed by incubation with
goat anti-mouse IgG/IgM antibody conjugated to FITC. As control, cells
were incubated with binding buffer instead of native EgAgB (PBS), without
adding EB7 mab (w/EB7) or using mouse IgG1 kappa isotype control
instead of EB7 mab (IC). In left panels figure shows the histograms
with the distribution of cell population as function of FITC fluorescence for
controls (grey) and EgAgB-treated cells (red). Histograms are representative
of three independent experiments for each cell type. In right panels binding
indexes were plotted vs. native EgAgB concentrations (1 and 10 μg/ml) for
monocytes (upper panels) and macrophages (bottom panels). Data are
expressed as mean ± SEM of three independent experiments. Asterisks
(*) indicate significant differences with respect to the control with BB
according to the analysis by t-test (p < 0.05), while number signs (#)
indicate significant differences in the binding indexes obtained at 1
and 10 μg/ml native EgAgB (one-way ANOVA followed by Tukey’s
post-test, p < 0.05). (TIF 11689 kb)
Additional file 7: Effects of EgAgB on IL-10 production by
macrophages. THP-1 macrophages were stimulated with LPS (0.1 ng/
ml) for 12 h in absence or presence of increasing concentrations of
EgAgB. Secretion of IL-10 was determined by ELISA in cell culture
supernatant and expressed as the fold-increase related to the basal
secretion (normalised against the medium condition). Results
correspond to mean values ± SEM of two independent experiments.
Number signs (#) indicate significant differences with respect to the
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medium condition according to one-way ANOVA analysis followed by
Tukey’s post-test (p < 0.05). (TIF 24 kb)
Additional file 8: Determination of arginase activity in bone
marrow-derived macrophages stimulated with EgAgB. Arginase
activity was evaluated in BMDM incubated with PBSEB (control),
immunopurified EgAgB (0.2–20 μg/mL), or murine IL-4 (2.5 ng/ml) as a
control of macrophage alternative activation. Arginase activity was
expressed as mU per million of BMDM. The graph is representative of
three independent experiments. Bars indicate SEM of analytical triplicates.
Asterisks (*) indicate significant differences with respect to the control
(medium) according to one-way ANOVA analysis followed by Tukey’s
post-test (p < 0.05). (TIF 27 kb)
Abbreviations
BB: Binding buffer (PBS containing 1 % (v/v) FS and 0.1 % NaN3);
BMDM: Bone marrow derived macrophages; EgAgB: Antigen B from
Echinococcus granulosus; EgAgBPLD-: Control EgAgB for treatment with PLD;
EgAgBPLD+: EgAgB treated with PLD; fQS: Q-Sepharose retained fraction;
GL: Germinal layer; HDL: High-density lipoprotein; HF: Hydatid cyst fluid;
HLBPs: Hydrophobic Ligand Binding Proteins; HPTLC: High performance thin
layer chromatography; iBAQ: Intensity-based absolute quantification; LC-MS/
MS: Liquid chromatography–mass spectrometry; LDL: Low-density
lipoprotein; LDLr: LDL receptor; LPS: Lipopolysaccharides; LRP1: LDL receptor
related protein 1; MALDI-TOF/TOF: Matrix-assisted laser desorption/ionization
time-of-flight; OVA: Ovalbumin; PBSEB: PBS containing 5 mM EDTA and
20 μM BHT; PC: Phosphatidylcholine; PC/PS-LUVs: Large unilamellar vesicles
composed of PC and PS (50:50 mol:mol); PC-LUVs: Large unilamellar vesicles
composed of PC; PLD: Phospholipase D; PS: Phosphatidylserine;
rEgAgB8: recombinant lipid-free EgAgB8 subunits; RP-HPLC: Reversed-phase
high performance liquid chromatography; SR-A: Class A scavenger receptor.
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